290 related articles for article (PubMed ID: 29668117)
1. Development of Molecular Therapies for Venous Malformations.
Kangas J; Nätynki M; Eklund L
Basic Clin Pharmacol Toxicol; 2018 Sep; 123 Suppl 5():6-19. PubMed ID: 29668117
[TBL] [Abstract][Full Text] [Related]
2. A xenograft model for venous malformation.
Goines J; Li X; Cai Y; Mobberley-Schuman P; Metcalf M; Fishman SJ; Adams DM; Hammill AM; Boscolo E
Angiogenesis; 2018 Nov; 21(4):725-735. PubMed ID: 29786783
[TBL] [Abstract][Full Text] [Related]
3. New and Emerging Targeted Therapies for Vascular Malformations.
Van Damme A; Seront E; Dekeuleneer V; Boon LM; Vikkula M
Am J Clin Dermatol; 2020 Oct; 21(5):657-668. PubMed ID: 32557381
[TBL] [Abstract][Full Text] [Related]
4. Rapamycin improves TIE2-mutated venous malformation in murine model and human subjects.
Boscolo E; Limaye N; Huang L; Kang KT; Soblet J; Uebelhoer M; Mendola A; Natynki M; Seront E; Dupont S; Hammer J; Legrand C; Brugnara C; Eklund L; Vikkula M; Bischoff J; Boon LM
J Clin Invest; 2015 Sep; 125(9):3491-504. PubMed ID: 26258417
[TBL] [Abstract][Full Text] [Related]
5. Somatic Activating PIK3CA Mutations Cause Venous Malformation.
Limaye N; Kangas J; Mendola A; Godfraind C; Schlögel MJ; Helaers R; Eklund L; Boon LM; Vikkula M
Am J Hum Genet; 2015 Dec; 97(6):914-21. PubMed ID: 26637981
[TBL] [Abstract][Full Text] [Related]
6. Ponatinib Combined With Rapamycin Causes Regression of Murine Venous Malformation.
Li X; Cai Y; Goines J; Pastura P; Brichta L; Lane A; Le Cras TD; Boscolo E
Arterioscler Thromb Vasc Biol; 2019 Mar; 39(3):496-512. PubMed ID: 30626204
[TBL] [Abstract][Full Text] [Related]
7. Review of the endothelial pathogenic mechanism of TIE2-related venous malformation.
Du Z; Zheng J; Zhang Z; Wang Y
J Vasc Surg Venous Lymphat Disord; 2017 Sep; 5(5):740-748. PubMed ID: 28818232
[TBL] [Abstract][Full Text] [Related]
8. PIK3CA mutations in vascular malformations.
Castillo SD; Baselga E; Graupera M
Curr Opin Hematol; 2019 May; 26(3):170-178. PubMed ID: 30855339
[TBL] [Abstract][Full Text] [Related]
9. Somatic activating mutations in Pik3ca cause sporadic venous malformations in mice and humans.
Castillo SD; Tzouanacou E; Zaw-Thin M; Berenjeno IM; Parker VE; Chivite I; Milà-Guasch M; Pearce W; Solomon I; Angulo-Urarte A; Figueiredo AM; Dewhurst RE; Knox RG; Clark GR; Scudamore CL; Badar A; Kalber TL; Foster J; Stuckey DJ; David AL; Phillips WA; Lythgoe MF; Wilson V; Semple RK; Sebire NJ; Kinsler VA; Graupera M; Vanhaesebroeck B
Sci Transl Med; 2016 Mar; 8(332):332ra43. PubMed ID: 27030595
[TBL] [Abstract][Full Text] [Related]
10. Common and specific effects of TIE2 mutations causing venous malformations.
Nätynki M; Kangas J; Miinalainen I; Sormunen R; Pietilä R; Soblet J; Boon LM; Vikkula M; Limaye N; Eklund L
Hum Mol Genet; 2015 Nov; 24(22):6374-89. PubMed ID: 26319232
[TBL] [Abstract][Full Text] [Related]
11. [Rapamycin opens the era of targeted molecular therapy of venous malformations].
Seront E; Limaye N; Boon LM; Vikkula M
Med Sci (Paris); 2016; 32(6-7):574-8. PubMed ID: 27406763
[No Abstract] [Full Text] [Related]
12. Comprehensive phenotypic and genomic characterization of venous malformations.
Hirose K; Hori Y; Ozeki M; Motooka D; Hata K; Tahara S; Matsui T; Kohara M; Maruyama K; Imanaka-Yoshida K; Toyosawa S; Morii E
Hum Pathol; 2024 Mar; 145():48-55. PubMed ID: 38367816
[TBL] [Abstract][Full Text] [Related]
13. Genetic landscape of common venous malformations in the head and neck.
Du Z; Liu JL; You YH; Wang LZ; He J; Zheng JW; Zhang ZY; Wang YA
J Vasc Surg Venous Lymphat Disord; 2021 Jul; 9(4):1007-1016.e7. PubMed ID: 33248299
[TBL] [Abstract][Full Text] [Related]
14. AKT/FOXO1 axis links cross-talking of endothelial cell and pericyte in TIE2-mutated venous malformations.
Si Y; Huang J; Li X; Fu Y; Xu R; Du Y; Cheng J; Jiang H
Cell Commun Signal; 2020 Aug; 18(1):139. PubMed ID: 32867785
[TBL] [Abstract][Full Text] [Related]
15. Tie2-R849W mutant in venous malformations chronically activates a functional STAT1 to modulate gene expression.
Hu HT; Huang YH; Chang YA; Lee CK; Jiang MJ; Wu LW
J Invest Dermatol; 2008 Sep; 128(9):2325-33. PubMed ID: 18401423
[TBL] [Abstract][Full Text] [Related]
16. CD10 and CD34 as markers in vascular malformations with PIK3CA and TEK mutations.
Moneghini L; Tosi D; Graziani D; Caretti A; Colletti G; Baraldini V; Cattaneo E; Spaccini L; Zocca A; Bulfamante GP
Hum Pathol; 2020 May; 99():98-106. PubMed ID: 32272124
[TBL] [Abstract][Full Text] [Related]
17. Treatment of voluminous and complicated superficial slow-flow vascular malformations with sirolimus (PERFORMUS): protocol for a multicenter phase 2 trial with a randomized observational-phase design.
Maruani A; Boccara O; Bessis D; Guibaud L; Vabres P; Mazereeuw-Hautier J; Barbarot S; Chiaverini C; Blaise S; Droitcourt C; Mallet S; Martin L; Lorette G; Woillard JB; Jonville-Bera AP; Rollin J; Gruel Y; Herbreteau D; Goga D; le Touze A; Leducq S; Gissot V; Morel B; Tavernier E; Giraudeau B;
Trials; 2018 Jun; 19(1):340. PubMed ID: 29945674
[TBL] [Abstract][Full Text] [Related]
18. PI3K/mTOR inhibition promotes the regression of experimental vascular malformations driven by PIK3CA-activating mutations.
di Blasio L; Puliafito A; Gagliardi PA; Comunanza V; Somale D; Chiaverina G; Bussolino F; Primo L
Cell Death Dis; 2018 Jan; 9(2):45. PubMed ID: 29352118
[TBL] [Abstract][Full Text] [Related]
19. Somatic TEK variant with intraarticular venous malformation and knee hemarthrosis treated with rapamycin.
Adham S; Revencu N; Mestre S; Nou-Howaldt M; Vernhet-Kovacsik H; Quéré I
Mol Genet Genomic Med; 2022 Jun; 10(6):e1931. PubMed ID: 35426265
[TBL] [Abstract][Full Text] [Related]
20. Classification and Tie2 mutations in spinal and soft tissue vascular anomalies.
Zhou M; Jiang R; Zhao G; Wang L; Wang H; Li W; Li Y; Du X; Bai J
Gene; 2015 Oct; 571(1):91-6. PubMed ID: 26115772
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
